ERBB2 and breast cancer: We performed a comparison of our cohort with early breast cancer (eBC) in The Cancer Genome Atlas (TCGA): No significant difference in HRD score was found between early BRCA mutated tumors from TCGA, and metastatic BRCA mutated tumor from our cohort, since S3 level was slightly higher in ER+/HER2− patients in our cohort than in TCGA.